N,N Dimethylacetamide a drug excipient that acts as bromodomain ligand for osteoporosis treatment.

Abstract

N,N-Dimethylacetamide (DMA) is a water-miscible solvent, FDA approved as excipient and therefore widely used as drug-delivery vehicle. As such, DMA should be devoid of any bioactivity. Here we report that DMA is epigenetically active since it binds bromodomains and inhibits osteoclastogenesis and inflammation. Moreover, DMA enhances bone regeneration in vivo. Therefore, our in vivo and in vitro data reveal DMA's potential as an anti-osteoporotic agent via the inhibition of osteoclast mediated bone resorption and enhanced bone regeneration. Our results highlight the potential therapeutic benefits of DMA and the need for reconsideration of previous reports where DMA was used as an 'inactive' drug-delivery vehicle.

• Authors: Chafik Ghayor, Bebeka Gjoksi, Jing Dong, Barbara Siegenthaler, Amedeo Caflisch, Franz E Weber
• Journal: Scientific reports (Sci Rep) Vol. 7 Pg. 42108 (02 08 2017) ISSN: 2045-2322 [Electronic] England
• PMID: 28176838 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Acetamides
• Anti-Inflammatory Agents
• BRD4 protein, human
• Bone Density Conservation Agents
• Cell Cycle Proteins
• Excipients
• Nuclear Proteins
• Transcription Factors
• dimethylacetamide

Topics

• Acetamides (pharmacology)
• Animals
• Anti-Inflammatory Agents (pharmacology)
• Bone Density Conservation Agents (pharmacology)
• Cell Cycle Proteins
• Cell Line
• Excipients (pharmacology)
• Female
• Humans
• Mice
• Nuclear Proteins (metabolism)
• Osteogenesis (drug effects)
• Protein Binding
• Rats, Sprague-Dawley
• Transcription Factors (metabolism)